1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Malignancy: new trials by email Literature Review of Malignancy trials Research Report on Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Etoposide, Interferon-alpha, Rituximab - Lymphoproliferative Disorder, HHV-8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 75 | 2004-10-28 | 2026-10-29 |
HIV Infections (1) · Lymphadenopathy (1) · Lymphoproliferative Disorders (1) · Macular dystrophy, corneal type 1 (1) · Multi-centric Castleman's Disease (1) · Neoplasms (1)
Blood-Borne Infections (1) · Communicable Diseases (1) · Genital Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Immunoproliferative Disorders (1) · Infections (1) · Lentivirus Infections (1) · Lymphatic Diseases (1) · RNA Virus Infections (1) · Retroviridae Infections (1) · Sexually Transmitted Diseases (1) · Sexually Transmitted Diseases, Viral (1) · Urogenital Diseases (1)
Bortezomib (1) · Cyclophosphamide (1) · Doxorubicin (1) · Etoposide (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Interferon-alpha (1) · Prednisone (1) · Rituximab (1) · Sirolimus (1) · Valganciclovir (1) · Vincristine (1) · Zidovudine (1) · liposomal doxorubicin (1)
National Cancer Institute (NCI) (1)
United States (1)
PMID 21487108, PMID 24174627, PMID 25331113, PMID 33720337, PMID 38941593, PMID 41845569